Atezolizumab/Bevacizumab beim hepatozellulären KarzinomAtezolizumab/Bevacizumab in hepatocellular carcinoma

被引：0
|
作者：
Fabian Kütting
Hakan Alakus
Christiane Bruns
机构：
[1] Universitätsklinikum Köln (AöR),Klinik für Gastroenterologie und Hepatologie
[2] Universitätsklinikum Köln (AöR),Klinik und Poliklinik für Allgemein‑, Viszeral
来源：
Der Onkologe | 2020年 / 26卷 / 10期
关键词：
D O I：
10.1007/s00761-020-00807-5
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：970 / 971
页数：1
相关论文
共 50 条
  • [31] Bayesian Analysis Supports Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma
    Rizzo, Alessandro
    Ricci, Angela Dalia
    Brandi, Giovanni
    LIVER CANCER, 2022, 11 (02) : 180 - 181
  • [32] Neoadjuvant atezolizumab plus bevacizumab prior liver transplantation for hepatocellular carcinoma
    Tabrizian, Parissa
    Marino, Rebecca
    Bhoori, Sherrie
    Zeitlhoefler, Marcus
    Mehta, Neil
    Banz, Vanessa
    Gruttadauria, Salvatore
    Iavarone, Massimo
    Mazzarelli, Chiara
    Simonotti, Nicolo
    Yao, Francis
    Mazzaferro, Vincenzo
    Llovet, Josep M.
    JHEP REPORTS, 2025, 7 (02)
  • [33] Impact of older age in patients receiving atezolizumab and bevacizumab for hepatocellular carcinoma
    Vithayathil, Mathew
    D'Alessio, Antonio
    Fulgenzi, Claudia A. M.
    Nishida, Naoshi
    Schoenlein, Martin
    von Felden, Johann
    Schulze, Kornelius
    Wege, Henning
    Saeed, Anwaar
    Wietharn, Brooke
    Hildebrand, Hannah
    Wu, Linda
    Ang, Celina
    Marron, Thomas U.
    Weinmann, Arndt
    Galle, Peter R.
    Bettinger, Dominik
    Bengsch, Bertram
    Vogel, Arndt
    Balcar, Lorenz
    Scheiner, Bernhard
    Lee, Pei-Chang
    Huang, Yi-Hsiang
    Amara, Suneetha
    Muzaffar, Mahvish
    Naqash, Abdul Rafeh
    Cammarota, Antonella
    Personeni, Nicola
    Pressiani, Tiziana
    Pinter, Matthias
    Cortellini, Alessio
    Kudo, Masatoshi
    Rimassa, Lorenza
    Pinato, David J.
    Sharma, Rohini
    LIVER INTERNATIONAL, 2022, 42 (11) : 2538 - 2547
  • [34] Duodenal Variceal Rupture during Atezolizumab and Bevacizumab Treatment for Hepatocellular Carcinoma
    Tsuruoka, Mio
    Inoue, Jun
    Ouchi, Keishi
    Uno, Kaname
    Itami, Hideaki
    Ninomiya, Masashi
    Iwata, Tomoaki
    Sano, Akitoshi
    Sato, Kosuke
    Onuki, Masazumi
    Sawahashi, Satoko
    Koike, Tomoyuki
    Masamune, Atsushi
    INTERNAL MEDICINE, 2023, 62 (10) : 1467 - 1472
  • [35] Cost-effectiveness of atezolizumab and bevacizumab in advanced hepatocellular carcinoma.
    Patel, Kishan
    Stein, Stacey
    Luther, Janki
    Huntington, Scott F.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [36] Fibrolamellar hepatocellular carcinoma treated with atezolizumab and bevacizumab: two case reports
    Ali AL Zahrani
    Ali Alfakeeh
    Journal of Medical Case Reports, 15
  • [37] New approval: Atezolizumab and bevacizumab for first line of unresecable hepatocellular carcinoma
    Minot-This, Marie-Sophie
    Edeline, Julien
    BULLETIN DU CANCER, 2021, 108 (02) : 139 - 140
  • [38] Letter to the editor: Atezolizumab plus bevacizumab for hepatocellular carcinoma in the real world
    Zhang, Junwei
    Fang, Jinyu
    Xun, Ziyu
    Xu, Yiyao
    Lu, Xin
    Zhao, Haitao
    HEPATOLOGY, 2022, 76 (04) : E84 - E85
  • [39] Treatment Outcomes and Toxicities for Patients with Hepatocellular Carcinoma Treated with Atezolizumab and Bevacizumab
    Pakeerathan, Veenaa
    Babu, Hari
    Andelkovic, Vladimir
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2024, 20 : 54 - 55
  • [40] Tumor microenvironment and clinical efficacy of atezolizumab plus bevacizumab for hepatocellular carcinoma
    Taira, Tomonao
    Kojima, Motohiro
    Yamaguchi, Shota
    Inoue, Kanae
    Eguchi, Hiroki
    Okumura, Kei
    Shibuki, Taro
    Satake, Tomoyuki
    Watanabe, Kazuo
    Sasaki, Mitsuhito
    Imaoka, Hiroshi
    Mitsunaga, Shuichi
    Ishii, Genichiro
    Ikeda, Masafumi
    ANNALS OF ONCOLOGY, 2023, 34 : S1399 - S1399
12345